Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuzatrelvir with or without remdesivir for severely immunocompromised adults with COVID-19
NL-OMON59973Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing Ibuzatrelvir monotherapy with Ibuzatrelvir plus remdesivir (2 arms). Primary endpoint: Composite clinical and virologic failure endpoint by Day 38. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ibuzatrelvirremdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON59973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59973.